Drug Database
TR

trastuzumab (BP 02 / BP02)

✓ Approved

Aurobindo Pharma Limited · ERBB2 · 单克隆抗体

什么是 trastuzumab?

trastuzumab 是一种单克隆抗体,由Aurobindo Pharma Limited研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名BP 02, BP02
公司Aurobindo Pharma Limited
药物类别单克隆抗体, 抗体
分子靶点ERBB2, LRP1
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

trastuzumab 作用于 2 个分子靶点:

ERBB2erb-b2 receptor tyrosine kinase 2 (NEU, CD340)
LRP1LDL receptor related protein 1 (LRP1A, A2MR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

trastuzumab 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Gastric cancerBLA/NDA

相关研究文献

PubMedClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2026-11-19

Longitudinal Blood Eosinophil Profiles and Response to Anti-IL-5/IL-5Rα Biologics in Severe Asthma.

Betancor Diana D, Laorden Daniel D, Rozo Mariana M, Vecillas Leticia De Las LL et al.

PMID 43053496
阅读全文 →
PubMedEye (London, England)2026-11-19

Comprehensive evaluation of drug-related vision disorder risk in breast cancer patients: a global pharmacovigilance analysis.

Chen Heng H, Hou Ju J, Song Hui H, Ouyang Lihui L et al.

Breast cancer, the most common malignancy in women worldwide, has a high incidence and mortality rate, with treatments like chemotherapy and targeted therapies improving survival but causing ocular toxicity. In this study, we analysed potential risk signals for vision disorders in breast cancer patients using the FAERS from January 2020 to December 2024. Disproportionate analysis was performed to identify positive signals, with a reporting odds ratio (ROR). Multiplicative models were used to assess drug-drug interactions. Moreover, the time to onset of vision disorders was also evaluated. A total of 2402 cases of vision disorders occurring in breast cancer patients were included. The median onset time for vision disorders was 17.5 days (IQR: 2.5-84.5), with hospitalisation (19.9%) and disability (7.4%) as common outcomes. Among the top 20 most frequently used drugs, tamoxifen (ROR = 2.29, 95% CI: 1.68-3.13) and trastuzumab emtansine (ROR = 1.98, 95% CI: 1.49-2.64) showed the strongest associations with vision disorders. Combination therapy analysis identified positive interaction signals for ribociclib with most endocrine therapies. This study systematically evaluated potential risk signals for vision disorders associated with medication use in breast cancer patients. These findings may support clinical vigilance for potential ocular AEs but do not quantify treatment risk or establish causality.

PMID 43052412
阅读全文 →
PubMedCardio-oncology (London, England)2026-11-19

Assessment of the HFA-ICOS risk tool for predicting cancer therapy-related cardiac dysfunction: a prospective cohort study.

Guerra Enrique C EC, Aparicio-Ortiz Alexis D AD, Barac Ana A, Asch Federico M FM et al.

Anthracyclines and HER2-targeted breast cancer treatments can cause cancer therapy-related cardiac dysfunction (CTRCD). The Heart Failure Association-International Cardio-Oncology Society (HFA-ICOS) risk tool assesses this risk, but its accuracy remains uncertain. We aimed to (1) determine CTRCD incidence using the 2021 CTRCD definition in breast-cancer patients receiving doxorubicin and/or trastuzumab; (2) evaluate the HFA-ICOS risk proformas, and (3) assess the individual risk factors incorporated in the proformas. In this prospective study, 186 women with early-stage breast cancer were enrolled to undergo baseline and serial cardiac evaluations over 12 months. After exclusions, 177 patients were included for risk stratification using the Heart Failure Association-International Cardio-Oncology Society (HFA-ICOS) score. Baseline risk distribution was 67% low (n = 116), 28% moderate (n = 52), and 5% high (n = 9). During follow-up, 53 patients (28.6%) developed cancer therapy-related cardiac dysfunction (CTRCD), corresponding to an overall incidence rate of 0.266 events per person-year (95% CI 0.200-0.348). Incidence rates were 0.326, 0.145, and 0.248 in the low-, moderate-, and high-risk groups, respectively; pairwise 365-day restricted mean survival time (RMST) comparisons did not remain statistically significant after Holm adjustment (all adjusted p > = 0.124). In Cox models adjusted for treatment type, CTRCD risk did not differ significantly between the moderate- and high-risk groups compared with the low-risk group. The ordinal HFA-ICOS category showed poor discrimination for time to CTRCD (Harrell C-index 0.43, 95% CI 0.37-0.49). The HFA-ICOS proforma showed limited ability to stratify CTRCD risk in this cohort. These findings highlight limitations in current guideline-based risk models and the need for improved stratification strategies.

PMID 43053233
阅读全文 →
PubMedTherapeutic advances in vaccines and immunotherapy2026-11-18

Current use of antimicrobial preservatives in multi-dose vaccines and biologics.

Park Noa N, Abdolrahimi Shiva S, Behrens Sue S

Antimicrobial preservatives (APs) offer significant advantages when included in multi-dose vaccines (MDVs) and biologics. In addition to reducing medical waste and optimizing overall manufacturing efficiency, MDVs with APs increase global access to critical medicines and meet public health demands. Phenol, metacresol, benzyl alcohol, benzethonium chloride, thimerosal, and phenoxyethanol are currently the only APs included in FDA-approved biologics and WHO prequalified vaccines. The mechanisms of actions of these six APs, however, may limit their suitability for certain biologics, namely RNA-based vaccines. Novel antimicrobial agents, such as zinc salts and chitosan, may be considered for further investigation and potential use as alternative APs. Including APs in biologics gives rise to additional manufacturing considerations pertaining to drug product quality and stability. In addition, antimicrobial agents have not yet been tested or approved for use in RNA-based vaccines, which highlights important implications for access and shelf-life.

PMID 43048446
阅读全文 →
PubMedFrontiers in oncology2026-11-18

Case Report: Trastuzumab-deruxtecan as 11th line therapy in a metastasized ovarian clear cell carcinoma patient expressing HER2 1.

Wolfrum Angelika A, Ladurner Julia J, Abendstein Burghard B

Ovarian clear cell carcinoma (OCCC) is a rare histologic subtype of epithelial ovarian cancer, accounting for approximately 5%-10% of cases in Western populations. Compared with high-grade serous ovarian cancer, OCCC is characterized by lower sensitivity to conventional cytotoxic chemotherapy and consequently poor outcomes. Given the limited efficacy of standard systemic therapies, there is a considerable unmet need for novel treatment strategies in OCCC. Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic class across several solid tumors. Among these agents, trastuzumab deruxtecan (TDXd) has demonstrated substantial clinical activity in HER2-expressing malignancies and has recently shown efficacy across multiple tumor types in the DESTINY-PanTumor02 trial, but with low evidence in OCCC. Here, we report a patient with heavily pretreated recurrent ovarian clear cell carcinoma who achieved a durable and clinically meaningful response to trastuzumab deruxtecan despite low HER2 expression (IHC 1+).

PMID 43047483
阅读全文 →
PubMedTherapeutic advances in gastroenterology2026-11-18

Comment on: Pregnancy safety of biologics in inflammatory bowel disease: A systematic review and network meta-analysis.

Mela Liverinto-Panagiotis LP

PMID 43048405
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多trastuzumab